Wednesday, 24 July 2013

India poised to revoke Pioglitazone ban

The Drug Technical Advisory Board (DTAB) has advised the Government to revoke the suspension of the diabetes drug pioglitazone. 

The DTAB met on July 19 and recommended that pioglitazone be put back in the market in India with a box warning about bladder cancer.

The DTAB is an advisory body and the government may or may not accept its advice but it is likely that the recommendations may be accepted. 

No comments:

Post a Comment